Destination therapy: patient selection and current outcomes.
Long-term left-ventricular assist device (LVAD) support as destination therapy (DT) is a promising new alternative for the growing population of patients with advanced heart failure. In this article, we summarize the clinical trials that led to the approval of LVAD use as DT in the US national policies regulating candidate selection and DT center accreditation. We review current guidelines for candidate selection, clinical tools to assess candidate operative risk, and outcomes of DT.
Center for Advanced Heart Failure and Transplantation, Yale University School of Medicine, New Haven, Connecticut 06520-8017, USA. Katherine.Lietz@yale.edu
Katherine
K
Lietz
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use; D004867:Equipment Design; D006333:Heart Failure / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D006353:Heart-Assist Devices / Q000191:economics / Q000706:statistics & numerical data*; D006801:Humans; D018579:Patient Selection; D012307:Risk Factors; D016896:Treatment Outcome; D014481:United States
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002316:Cardiotonic Agents